Iovance Biotherapeutics, Inc.

NASDAQ:IOVA

Biotechnology

Healthcare
$7.48 -0.89%

-$0.04 today

Market cap
$3.46B
Beta
0.70
P/E (TTM)
-4.6
EPS (TTM)
-$0.85
52W Low $1.66High $5.63

Volume 6.99M

Average 14.09M

IOVA Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Iovance Biotherapeutics, Inc.NASDAQ: IOVA

Operating Margin · Q3 FY2026 · quarter ended Sep 2026

Operating margin widens to -19.7%

Operating margin was -19.7% in Q3 FY2026, up 113.3 pp from a year earlier. On a trailing-twelve-month basis it was -60.8%, up 103.5 pp year over year.

Context

  • Operating margin widened in 2 of the last 2 fiscal years.
  • FY2025 was the highest level in the 3 fiscal years shown.

What to watch

Whether operating margin reaches the consensus estimate from 5 analysts of -40.4% for the fiscal year ending Dec 2026, up from -151.1% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
-19.7%+32.5 pp QoQ
Last fiscal yearDec 2025
-151.1%+89.8 pp YoY
LTMSep 2026
-60.8%+103.5 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+113.3 pp+69.1 pp-44.3 pp
1 year+89.8 pp+110.8 pp+21.0 pp
3 years—+168.7 pp—
5 years+169.5 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
-151.1%
Year-over-year change
+89.8pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How IOVA compares with its peers on the latest reported figures

  • IOVA's LTM Sep 2026 operating margin of -60.8% is the 4th highest of the 9 companies compared; the peer median is -111.0%.
  • Its year-over-year change of +103.5 pp is the 3rd highest of 8, against a peer median of +6.7 pp.
IOVA Competitors Peer median
Operating Margin for IOVA and competitors
Company Period LTM level YoY 3-year change
GMABGenmab A/SLTM Jun 202632.3% —-9.6 pp
LEGNLegend Biotech CorporationLTM Sep 20262.5% +23.5 pp+376.1 pp
IMCRImmunocore Holdings plcLTM Mar 2026-7.6% +6.7 pp+18.3 pp
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026-60.8% +103.5 pp—
BNTXBioNTech SELTM Jun 2026-71.8% -41.3 pp-95.7 pp
IBRXImmunityBio, Inc.LTM Sep 2026-150.2% +165.7 pp+146148.2 pp
FATEFate Therapeutics, Inc.LTM Mar 2026-2207.5% -704.0 pp-1902.2 pp
IMNMImmunome, Inc.FY2025-3084.8% +297.6 pp—
STTKShattuck Labs, Inc.LTM Mar 2026-5266.4% -3640.0 pp+10697.2 pp
REPLReplimune Group, Inc.FY2025— ——
ALXOALX Oncology Holdings Inc.FY2025— ——
Peer median (excluding IOVA) -111.0%+6.7 pp+18.3 pp

Competitors are the stored peer set for IOVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue001.19M164.07M263.5M
Cost of Revenue0010.76M124M173.18M
Gross Profit00(9.57M)40.08M90.32M
Gross Margin——-804.5%24.4%34.3%
Research & Development259.04M294.78M344.08M282.34M300.27M
Selling, General & Admin83.66M104.1M106.92M153.02M152.32M
Operating Expenses342.7M398.88M450.99M435.35M488.53M
Depreciation & Amortization13.98M21.14M33.13M43.61M47.32M
EBITDA(328.27M)(371.77M)(414.39M)(331.4M)(350.89M)
EBITDA Margin——-34851.9%-202.0%-133.2%
Operating Income(342.7M)(398.88M)(460.56M)(395.28M)(398.21M)
Operating Margin——-38735.0%-240.9%-151.1%
Interest Income451K2.99M13.04M20.27M10.31M
Interest Expense02.99M000
Other Income / Expenses451K2.99M13.04M20.27M5.16M
Income Before Tax(342.25M)(395.89M)(447.52M)(375.01M)(393.05M)
Pre-Tax Margin——-37638.0%-228.6%-149.2%
Income Tax Expense00(3.48M)(2.83M)(2.07M)
Net Income(342.25M)(395.89M)(444.04M)(372.18M)(390.98M)
Net Margin——-37345.4%-226.8%-148.4%
EPS (Basic)(2.23)(2.49)(1.89)(1.28)(1.09)
EPS (Diluted)(2.23)(2.49)(1.89)(1.28)(1.09)
Weighted Avg Shares153.41M159.26M235.13M289.88M357.35M
Weighted Avg Shares (Diluted)153.41M159.26M235.13M289.88M357.35M

Iovance Biotherapeutics, Inc.

NASDAQ:IOVA

Intrinsic Alpha fair value

Locked

Current Price

$7.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.